Data from the BurstDR micrOdosing stimuLation in De-novo patients (BOLD) study found that BurstDR reduced pain catastrophizing scale scores (PCS) by an average of 62%. PCS is a patient reported measure used to determine how pain affects the mental state of a person experiencing chronic pain.
The research, which was presented at the 2020
'Chronic pain is a broad term that doesn't accurately capture the variety of issues and symptoms people experience as a result of it,' said
Additional data were also presented at NANS from the TRIUMPH study, a prospective, multi-center, single-arm, international study of 269 patients, which found significant improvements in physical, mental and emotional function were sustained for up to one-year, post-permanent implant. Patients also reported a reduction in the impact of pain on daily life, which resulted in patients becoming more active when measured at one year.
'These collective data illustrate the important and promising physical and mental health benefits of the BurstDR stimulation waveform for people living with chronic pain,' said
It is estimated that 50 million Americans live with chronic pain, which is defined as pain that lasts longer than six months. About 30% of those living with chronic pain develop depression or psychological effects when patients develop a preoccupation with pain that makes it difficult to live a normal life.
Abbott's Proclaim XR system allows physicians to identify the lowest effective dose of BurstDR stimulation customized to each patient, optimizing system longevity while maintaining effective pain and symptom relief, and eliminating the need for recharging (for up to 10 years at low-dose settings). This patient-centric innovation is possible because of Abbott's proprietary stimulation waveform and advanced battery technology that is integrated into Proclaim XR.
'We're still only scratching the surface of what spinal cord stimulation can do in patients experiencing chronic pain,' said
About Abbott's Chronic Pain Portfolio
Chronic pain can negatively impact personal relationships, work productivity and a person's daily routine. Abbott is a global leader in the development of chronic pain therapy solutions, offering radiofrequency therapy and spinal cord stimulation therapy solutions, including BurstDR stimulation, and dorsal root ganglion stimulation in the portfolio of chronic pain treatments. The Proclaim XR system is the latest advancement from Abbott, featuring upgradeable software and consumer-friendly technology that is compatible with Apple devices such as the iPad or iPod Touch.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.
Contact:
Tel: (512)-286-4217
(C) 2020 Electronic News Publishing, source